申请人:Merck Sharp & Dohme Corp.
公开号:US07816380B2
公开(公告)日:2010-10-19
α-Hydroxycycloalkanecarboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein formula (a) is a single or double bond; R1, R2 and R3 are each independently selected from H, halogen and OH; or R1 and R2 attached to the same carbon atom together represent oxo; R4 is H or methyl; R5 is Cl or I2; R6 is selected from —CO2—C1-4alkyl, —O—C1-4alkyl, —O—C1-4haloalkyl, 2-methyltetrazol-5-yl, 5-methyl-1,2,4-oxadiazol-3-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 5-halomethyl-1,2,4-oxadiazol-3-yl, 3-halomethyl-1,2,4-oxadiazol-5-yl, tetrazol-5-yl, 5-halomethyl-1,2,3-triazolyl, and 5-methyl-1,2,3-triazolyl; R7 and R8 are each independently Cl or I2; and n is 0 or 1, are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
式(I)或其药学上可接受的盐,其中式(a)表示单键或双键;R1、R2和R3各自独立地选择自H、卤素和OH;或者R1和R2结合到同一碳原子上表示氧代;R4为H或甲基;R5为Cl或I2;R6选择自—CO2—C1-4烷基、—O—C1-4烷基、—O—C1-4卤代烷基、2-甲基四唑-5-基、5-甲基-1,2,4-噁二唑-3-基、3-甲基-1,2,4-噁二唑-5-基、5-卤代甲基-1,2,4-噁二唑-3-基、3-卤代甲基-1,2,4-噁二唑-5-基、四唑-5-基、5-卤代甲基-1,2,3-三唑基和5-甲基-1,2,3-三唑基;R7和R8各自独立地为Cl或I2;n为0或1。这些化合物是Bradykinin B1拮抗剂或反向激动剂,用于治疗或预防与Bradykinin B1通路相关的疼痛和炎症等症状。